CSL (OTCMKTS:CSLLY) Reaches New 12-Month Low – What’s Next?
by Doug Wharley · The Cerbat GemShares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY – Get Free Report) reached a new 52-week low on Thursday . The company traded as low as $17.00 and last traded at $17.3150, with a volume of 901321 shares trading hands. The stock had previously closed at $17.73.
Analyst Ratings Changes
CSLLY has been the topic of a number of analyst reports. Royal Bank Of Canada cut CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, February 11th. Canaccord Genuity Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Zacks Research lowered shares of CSL from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Finally, Citigroup cut shares of CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce”.
Read Our Latest Research Report on CSLLY
CSL Stock Up 0.1%
The firm’s fifty day moving average is $22.04 and its 200 day moving average is $42.82. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57.
About CSL
CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.
The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.